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(57) ABSTRACT 
Primitive or progenitor hematologic cancer cells have been 
implicated in the early stages and development of leukemia 
and malignant lymphoproliferative disorders, including 
acute myelogenous leukemia (AML), chronic myelogenous 
leukemia (CML) and chronic lymphoid leukemia (CLL). 
Interleukin-3 receptor alpha chain (IL-3Ra or CD123) is 
strongly expressed on progenitor hematologic cancer cells, 
but is virtually undetectable on normal bone marrow cells. 
The present invention provides methods of impairing pro-
genitor hematologic cancer (e.g., leukemia and lymphomic) 
cells by selectively targeting cells expressing CD123. These 
methods are useful in the detection and treatment of leuke-
mias and malignant lymphoproliferative disorders. Also 
provided are compounds useful for selectively binding to 
CD123 and impairing progenitor hematologic cancer cells. 
These compounds may include cytotoxic moieties such as, 
for example, radioisotopes or chemotherapeutics. 
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METHODS TO IMPAIR HEMATOLOGIC 
CANCER PROGENITOR CELLS AND 
COMPOUNDS RELATED THERETO 
CONTINUING DATA 
The present application is a continuation of U.S. appli-
cation Ser. No. 12/636,263, filed Dec. 11, 2009, now U.S. 
Pat. No. 8,852,551, which is a continuation of U.S. appli-
cation Ser. No. 10/830,089, filed Apr. 23, 2004, now U.S. 
Pat. No. 7,651,678, which is a continuation of U.S. appli-
cation Ser. No. 09/799, 100, filed Mar. 6, 2001, now U.S. Pat. 
No. 6,733,743, which claims the benefit of priority to U.S. 
Provisional Patent Application Nos. 60/187,123, filed Mar. 
6, 2000, and 60/227,295, filed Aug. 24, 2000, the disclosures 
of each of which are incorporated by reference herein in 
their entirety. 
BACKGROUND OF THE INVENTION 
Field of the Invention 
The present invention is related to methods of impairing 
progenitor hematologic cancer cells or treating hematologic 
cancer by targeting a cell surface marker specific for pro-
genitor hematologic cancer cells. The present invention is 
also related to a method for diagnosing hematologic cancer. 
Background of the Invention 
Stem cells are commonly found in a variety of mamma-
lian tissue systems. While the criteria by which such cells are 
defined vary depending upon the specific context, two 
properties are generally regarded as central features of stem 
cell populations: (1) stem cells must exhibit some capacity 
for self-replication or self-renewal, and (2) stem cells must 
be capable of differentiating into appropriate lineages (Pat-
ten CS: Stem Cells. London, Academic Press, 1997). Cells 
2 
This disease is characterized by premature arrest of myeloid 
development and the subsequent accumulation of large 
numbers of non-functional leukemic blasts. While leukemic 
blast cells are often of clonal origin and display relatively 
5 homogeneous features, it has been demonstrated that such 
populations are organized in a hierarchical fashion, analo-
gous to normal hematopoietic progenitors. Thus, there is a 
phenotypically defined leukemic stem cell population that is 
sufficient to propagate leukemic blasts both in vitro and in 
10 vivo in xenogeneic mouse models of human AML (Bonnet 
D, et al., Human acute myeloid leukemia is organized as a 
hierarchy that originates from a primitive hematopoietic 
cell. Nat. Med. 1997, 3: 730-737; Blair A, et al., Most acute 
myeloid leukemia progenitor cells with long-term prolifera-
15 tive ability in vitro and in vivo have the phenotype CD34 
( + )/CD71(-)/HLA-DR-. Blood 1998, 92: 4325-35; 
Cobaleda C, et al., A primitive hematopoietic cell is the 
target for the leukemic transformation in human Philadel-
phia-positive acute lymphoblastic leukemia. Blood 2000, 
20 95: 1007-13; Blair A, et al. Lack of expression of Thy-1 
(CD90) on acute myeloid leukemia cells with long-term 
proliferative ability in vitro and in vivo. Blood 1997, 89: 
3104-12). The concept of a leukemic stem cell (LSC) 
becomes critically important in considering the etiology of 
25 human disease. Clearly, in order to achieve durable remis-
sion, it will be necessary to specifically ablate the primitive 
or progenitor LSC population. However, previous studies 
(Terpstra W, et al., Fluorouracil selectively spares acute 
myeloid leukemia cells with long-term growth abilities in 
30 immunodeficient mice and in culture. Blood 1996, 88: 
1944-50), as well as data from our group, suggest that LSC's 
are biologically distinct from more mature leukemic blasts 
and may not be responsive to conventional chemotherapeu-
tic regimens. This observation is consistent with the clinical 
35 profile frequently seen for AML, wherein a majority of 
patients can achieve apparent complete remission, but in 
most cases will relapse (Schiller G J., Treatment ofresistant 
disease. Leukemia 1998, 12 Suppl 1: S20-4; Paietta E., 
of this nature have been described for a number of tissues 
including hematopoietic, embryonic, neural, muscle and 
hepatic systems (Lemischka I R. Clonal, in vivo behavior of 
the totipotent hematopoietic stem cell. Semin Immunol 
1991, 3: 349-55; Morrison S J, et al., The biology of 40 
hematopoietic stem cells. Annu. Rev. Cell Dev. Biol. 1995, 
Classical multidrug resistance in acute myeloid leukemia. 
Med Oncol 1997, 14: 53-60). IfLSC's are more refractile to 
chemotherapy than blasts, it is attractive to propose that 
11: 35-71; Robertson E J., Using embryonic stem cells to 
introduce mutations into the mouse germ line. Biol Reprod 
1991, 44: 238-45; Gage F H., Mammalian neural stem cells. 
Science 2000, 287: 1433-8; and, Alison M, et al., Hepatic 
stem cells. J Hepatol 1998, 29: 676-82). Thus, it is perhaps 
not surprising that similar cells have recently been docu-
mented in the context of malignant populations (Bonnet D, 
et al., Human acute myeloid leukemia is organized as a 
hierarchy that originates from a primitive hematopoietic 
cell. Nat. Med. 1997, 3: 730-737; Blair A, et al., Most acute 
myeloid leukemia progenitor cells with long-term prolifera-
tive ability in vitro and in vivo have the phenotype CD34 
(+)/CD71(-)/HLA-DR-. Blood 1998, 92: 4325-35; 
Cobaleda C, et al., A primitive hematopoietic cell is the 
target for the leukemic transformation in human Philadel-
phia-positive acute lymphoblastic leukemia. Blood 2000, 
surviving stem cells are a major contributing factor to 
leukemic relapse. Thus, strategies that specifically target 
progenitor leukemia cells may provide more effective treat-
45 ment for leukemia patients. In 1997, Bonnet and Dick 
described the phenotype for LSC's as CD34+/CD38- (Bon-
net D, et al., Human acute myeloid leukemia is organized as 
a hierarchy that originates from a primitive hematopoietic 
cell. Nat. Med. 1997, 3: 730-737). We report that the IL-3 
50 receptor alpha chain (CD123) is highly expressed on leu-
kemic but not normal CD34+/CD38- hematopoietic cells. In 
view of this state of the art, there is a need in the art to 
provide a diagnostic method for detecting leukemia at an 
early stage, as well as more effective methods of treating this 
55 disease. 
SUMMARY OF THE INVENTION 
95: 1007-13). Indeed, a stem cell is in some respects the 
ideal target for malignant transformation in that relatively 
little biological change is required. Since stem cells already 60 
possess the genetic programming necessary to be highly 
proliferative and developmentally plastic, one can imagine 
that relatively subtle perturbations might be sufficient to 
induce disease. 
The present invention relates to a method of using com-
pounds that bind to the human CD123 molecule (CD123 
ectopeptide ), in the diagnosis and treatment of hematologic 
cancers (e.g., leukemias and malignant lymphoproliferative 
disorders). The CD123 specific compounds and mimetics 
have particular utility as pharmaceuticals and reagents for 
the therapy of hematologic cancer or malignant disease 
states and for the diagnosis of hematologic cancer disease 
states. In one embodiment, the present invention provides a 
One example of neoplasia arising from malignant stem 65 
cells has recently been documented in the hematopoietic 
system in the case of acute myelogenous leukemia (AML). 
US 10,508,150 B2 
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method of impairing a hematologic cancer progenitor cell 
comprising contacting the cell with a compound that selec-
tively binds to CD123 in an amount effective to impair the 
progenitor hematologic cancer cell. This contacting step 
may occur in various environments, including in vitro and in 5 
vivo in the body of an animal, including a human. 
accompanying drawings which are given by way of illus-
tration only, and thus are not limiting of the present inven-
tion, and wherein: 
FIGS. lA and 1B show CD123 expression on normal and 
leukemic hematopoietic cells. Representative examples of 
CD123 labeling in cells derived from normal bone marrow 
(panel A) or primary AML peripheral blood (panel B) are 
provided. The inset polygon in panel A (left dot plot) 
indicates the percentage of total bone marrow that is positive 
Throughout this application, reference will be made spe-
cifically to leukemia in describing certain embodiments of 
the present invention. However, it is understood that the 
present invention is not limited to diagnosis and treatment of 
10 leukemia or malignant lymphoproliferative disorders alone, 
but to any disease in which the cancerous cells selectively 
express CD123, which includes the genus of hematologic 
cancer. 
for CD123 expression (7%). The smaller rectangular gate 
indicates the proportion of total marrow strongly positive for 
CD123 (1%). The center dot plot in panel A shows bone 
marrow that was enriched for CD34+ cells by selection on 
an immunoaflinity colunm (see methods). The gates indicate In one embodiment, the present invention is directed to a 
method of detecting the presence of CD 123 on, for example, 
a leukemia progenitor cell. Thus, the invention is also 
directed to a method of diagnosing leukemia. It is under-
stood that by using a labeled ligand to bind to CD123, it is 
possible to detect the presence of leukemia progenitor cells. 
Thus, it is also possible to diagnose the likelihood of the 
onset of leukemia in patients possessing such leukemic 
progenitor cells expressing CD123. The CD123 binding 
ligand may be an antibody to CD123, or it may be any of a 
variety of molecules that specifically bind to CD123. Fur-
thermore, the label can be chosen from any of a variety of 
molecules, including, but not limited to, enzymatic com-
pounds, or non-enzymatic compounds that serve as a 
reporter of the presence of the ligand which has bound to the 
CD 123 molecule. Examples of such labels include those that 
are, for example, radioactive, fluorescent, chemiluminescent 
or absorbent-based, or a combination of the foregoing. In 
one embodiment, an assay is provided for detecting the 
presence of progenitor leukemia cells in a sample by detect-
ing the presence of CD123 in the sample, which may be 
accomplished by introducing a compound that selectively 
binds to CD123 and determining whether the compound 
binds to a component of the sample. 
In another series of embodiments, the present invention 
also provides compounds or molecules which mimic (mi-
metics) the three-dimensional structure of part or all of the 
compounds such as peptides, antibodies, carbohydrates, 
lipids or nucleic acids that bind to CD123, and in the case 
of antibodies, of the binding pockets of the antibodies, or of 
the complementarity determining regions (CDR's). 
The present invention also provides pharmaceutical 
preparations comprising a pharmaceutically acceptable car-
rier; and any one or more of the CD123 specific compounds 
and mimetics described above. 
In another set of embodiments, the present invention 
provides a method for the treatment ofleukemia, comprising 
administering to a human subject or other animal in need of 
such treatment a therapeutically effective amount of the 
compounds or their mimetic pharmaceutical compositions 
described above. 
In still another set of embodiments, the present invention 
provides a method of selectively purging leukemic stem 
cells from bone marrow. These stems cells may give rise to 
leukemia progenitor cells, or they may be the progenitor 
cells, which may be impaired by the method of the invention 
using various compounds or their mimetics and cytotoxic 
agents that may be contacted to either a bone marrow sample 
or injected into a bone marrow of an individual, thereby 
destroying at least some of the leukemic stem cells in the 
bone marrow. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The present invention will become more fully understood 
from the detailed description given herein below, and the 
15 the total CD34+ population and the CD34+/CD38- popu-
lation. The histograms indicate the CD123 labeling for the 
two gated populations. Panel B shows the same analysis for 
the primary AML specimen. Ml markers in the histograms 
indicate expression levels that are higher than 99% of 
20 isotype control samples. For each specimen, 50,000-100,000 
events were analyzed. 
FIG. 2 shows CD123 expression on five primitive AML 
populations. Five primary AML specimens were labeled 
with CD34, CD38, and CD123 and analyzed by flow cytom-
25 etry. The figure shows CD123 labeling for the CD34+/ 
CD38- gated populations from each sample. The dark 
sections indicate CD123 staining and the light sections 
indicate parallel labeling with an isotype control antibody. 
Ml markers in the histograms indicate expression levels that 
30 are higher than 99% of isotype control samples. For each 
specimen, 50,000-100,000 events were analyzed. 2A: 
Sample 1; 2B; Sample 2; 2C: Sample 3; 2D: Sample 4; 2E: 
Sample 5. 
FIGS. 3A and 3B show engraftment of CD123+ AML 
35 cells in NOD/SCID mice. Sorted CD34+/CD123+ primary 
AML cells were transplanted into an irradiated NOD/SCID 
mouse. Six weeks post-transplant, bone marrow cells were 
isolated and analyzed for the presence of human (CD45+) 
leukemic cells. Panel A shows the CD34 vs. CD45 profile of 
40 an engrafted specimen using antibodies that are specific to 
human cells. Panel B shows the CD34 vs. CD123 profile of 
the CD45+ gated human cell population. For each sample, 
50,000 events were analyzed. 
FIG. 4 shows CD123 and CD131 immunoblot analysis of 
45 primary AML specimens. Five primary AML samples were 
derived from peripheral blood and sorted to isolate the 
CD34+ population, thus insuring a virtually pure leukemic 
sample. In addition, the leukemic cell line TF-1 (TF-1) and 
normal marrow CD34+ cells (normal CD34+) were included 
50 as controls. Lysates were made from each population, sub-
ject to denaturing PAGE and analyzed by immunoblot with 
an anti-CD123 antibody (top panel) or an anti-CD131 anti-
body (bottom panel). The arrowhead at the left of each panel 
indicates the position of the IL-3Ra (CD123) and IL-3R~ 
55 (CD131) chains, respectively. 
FIGS. SA, SB and SC show phosphorylation of signal 
transduction components in response to IL-3. Three primary 
AML samples (Lanes 1-3) were derived from peripheral 
blood and sorted to isolate the CD34+ population. Samples 
60 were treated with ( +) or without (-) 20 ng/ml IL-3 for 15 
minutes, then lysed and subjected to PAGE. Each gel was 
then electro-blotted and membranes were probed with anti-
bodies specific to either total or phosphorylated protein for 
Akt (A), Stat5 (B), and Mek-l(C). The lane labeled C on 
65 each blot is an antibody control and is derived from NIH 3 T3 
cells treated +/-50 ng/ml PDGF (A and C), or TF-1 cells 
treated +/-25 ng/ml GM-SCF (B). 
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a large accumulation of non-functional immature cells and 
the concomitant loss of functional cells. Chronic leukemias 
progress more slowly, with cancer cells developing to full 
maturity. Furthermore, the white blood cells may be myel-
FIGS. 6A, 6B and 6C show CD123 expression in primary 
ALL. Flow cytometric analysis of CD123 expression on 
three independent primary ALL (acute lymphoid leukemia) 
specimens. CD123 labeling is shown by the filled (dark) 
plots and controls are shown by open plots. 
FIGS. 7A, 7B and 7C show CD123 expression in primary 
CML. Flow cytometric analysis of CD123 expression on 
three independent primary CML (chronic myelogenous leu-
kemia) specimens. CD123 labeling is shown by the filled 
(dark) plots and controls are shown by open plots. 
5 ogenous or lymphoid. Thus, certain forms of leukemia may 
be, by way of example, acute lymphatic (or lymphoblastic) 
leukemia (ALL); acute myelogenic leukemia (AML); 
chronic lymphocytic leukemia (CLL); or chronic myelo-
genic leukemia (CML); and myelodysplastic syndrome. 
DETAILED DESCRIPTION OF THE 
INVENTION 
10 "Malignant lymphoproliferative disorders" may refer to a 
lymphoma, such as multiple myeloma, non-Hodgkin's lym-
phoma, Burkitt's lymphoma, and follicular lymphoma 
(small cell and large cell), among others. For purposes of 
this invention, at least some of the hematologic cancer cells 
Definitions 15 are characterized by cells that express CD123. Also, for the 
purposes of this application, whenever leukemia or malig-
nant lymphoproliferative disorders are mentioned, the diag-
nostic and treatment method of the invention applies gen-
As used herein, the term "antibody" means an immuno-
globulin molecule, or a fragment of an immunoglobulin 
molecule, having the ability to specifically bind to a par-
ticular antigen. Antibodies are well known to those of 20 
ordinary skill in the science of immunology. As used herein, 
the term "antibody" means not only intact antibody mol-
ecules but also fragments of antibody molecules retaining 
antigen-binding ability. Such fragments are also well known 
in the art and are regularly employed both in vitro and in 25 
vivo. In particular, as used herein, the term "antibody" 
means not only intact immunoglobulin molecules but also 
the well-known active fragments F(ab')2 , Fab, Fv, Fd, V H 
and VL. 
As used herein, the terms "bind" or "bind(s)" shall mean 30 
any interaction, whether via direct or indirect means, which 
affects the specified receptor or receptor subunit. 
As used herein, the terms "binds selectively to" shall 
mean that the compound, composition, formulation, etc. 
does not significantly bind IL3R beta chain, but does bind 35 
IL3R alpha chain. 
As used herein, the terms "CD123", "IL3R subunit alpha" 
and "IL3Ra" shall be used interchangeably to mean an 
antigenic determinant that is detectable in leukemia precur-
sor cells as described herein, but not detectable on normal 40 
cells as described herein. 
As used herein, the term "compound" shall mean any 
purity of active ingredient, including formulations, compo-
sitions, naturally-occurring plants or animals, etc. The com-
pound may include molecules that are naturally occurring, 45 
such as proteins, nucleic acids, single stranded nucleic acids, 
lipids, carbohydrates, and antibodies. However, synthetic 
versions of these naturally occurring molecules may be 
made, so long as they bind CD123. The compounds may 
comprise more than one component. For example, a com- 50 
pound may be a monoclonal antibody attached to a toxin. Or, 
it may be a lipid attached to a label. The compounds may 
further comprise mimetics, and aptamers, but which all 
retain their specificity to CD123. 
As used herein, the term "impair" shall mean any decrease 55 
in functionality or activity (including growth or proliferative 
activity). 
As used herein, the term "hematologic cancer" refers to a 
cancer of the blood, and includes leukemia and malignant 
lymphoproliferative disorders, among others. "Leukemia" 60 
refers to a cancer of the blood, in which too many white 
blood cells that are ineffective in fighting infection are made, 
thus crowding out the other parts that make up the blood, 
such as platelets and red blood cells. It is understood that 
cases of leukemia are classified as acute or chronic. Cancer 65 
cells in acute leukemias are blocked at an immature stage. 
However, they continue to multiply. Consequently, there is 
erally to hematologic cancer. 
As used herein, the term "introducing" shall mean any 
means of delivery, whether in vivo or in vitro, including 
simple contact. 
As used herein, the term "mimetic" means a compound or 
molecule which mimics the three-dimensional structures of 
a site on CD123 to which a compound may bind, or the 
compound may be a molecule that mimics a molecule that 
binds to CD123. In the case of an anti-CD123 antibody 
binding site, or paratope, or active site, "mimetic" means a 
compound that mimics the three-dimensional structure of 
any combination of the antibody hypervariable loops or 
complementarity determining regions (CDR's). 
As used herein, the term "mimic" means the three-
dimensional placement of atoms of the mimetic such that 
similar ionic forces, covalent forces, van der Waal's or other 
forces, and similar charge complementarity, or electrostatic 
complementarity, exist between the atoms of the mimetic 
and the atoms of the binding site of the compound such as 
a peptide or an antibody such that the mimetic has a similar 
binding affinity for CD123 as the parent compound and/or 
such that the mimetic has a similar effect on the function of 
CD123 in vitro or in vivo. 
In the case of anti-CD123 antibodies, within the antigen-
binding portion of an antibody, as is well-known in the art, 
there are complementarity determining regions (CDRs), 
which directly interact with the epitope of the antigen, and 
framework regions (FRs), which maintain the tertiary struc-
ture of the paratope. In both the heavy chain Fd fragment and 
the light chain of IgG immunoglobulins, there are four 
framework regions (FRI through FR4) separated respec-
tively by three complementarity determining regions (CDRl 
through CDR3). The CDRs, and in particular the CDR3 
regions, and more particularly the heavy chain CDR3, are 
largely responsible for antibody specificity. 
As used herein, the term "normal" means any non-
pathogenic or non-pathology-related cells or conditions. 
As used herein, the terms "primitive" and "progenitor" 
shall be interchangeable. 
As used herein, with respect to polypeptides and antibod-
ies, the term "substantially pure" means that the polypep-
tides are substantially free of other substances with which 
they may be found in nature or in vivo systems to an extent 
practical and appropriate for their intended use. In particular, 
the polypeptides are sufficiently pure and are sufficiently free 
from other biological constituents of their host cells so as to 
be useful in, for example, generating antibodies, sequencing, 
or producing pharmaceutical preparations. By techniques 
well known in the art, substantially pure polypeptides may 
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Purely synthetic molecules, which may not occur in 
nature and are therefore more resistant to catabolism, excre-
tion or degradation, may be designed by the three-dimen-
sional placement of atoms, such that similar ionic forces, 
5 covalent forces, van der Waal's or other forces, and similar 
charge complementarity, or electrostatic complementarity, 
exist between the atoms of the mimetic and the atoms of the 
antigenic binding site or epitope. These mimetics may then 
be produced in light of the nucleic acid and amino acid 
sequences disclosed herein. Because a substantially purified 
polypeptide of the invention may be admixed with a phar-
maceutically acceptable carrier in a pharmaceutical prepa-
ration, the polypeptide may comprise only a small percent-
age by weight of the preparation. The polypeptide is 
nonetheless substantially pure in that it has been substan-
tially separated from the substances with which it may be 
associated in living systems. 
As used herein with respect to compounds or mimetics, 10 
the term "substantially pure" means that the compounds are 
substantially free of other substances with which they may 
be screened for high affinity binding to CD123 and detect 
and/or impair the CD123 bearing cell in vitro or in vivo, as 
described in more detail below. 
Diagnostic and Pharmaceutical Preparations 
The invention also relates to a method for preparing 
diagnostic or pharmaceutical compositions comprising the 
CD123 binding compound and its mimetics. The pharma-
ceutical preparation includes a pharmaceutically acceptable 
be found, in nature, in in vivo systems, or as a result of 
chemical or other synthesis, to an extent practical and 15 
appropriate for their intended use. In particular, the com-
pounds are sufficiently pure and are sufficiently free from 
other biological constituents of their hosts cells, or chemical 
carrier. Such carriers, as used herein, mean non-toxic mate-
rials that do not interfere with the effectiveness of the 
biological activity of the active ingredients. The term 
"physiologically acceptable" refers to a non-toxic material 
that is compatible with a biological system such as a cell, 
or physical constituents of their synthesis so as to be useful 
in, producing pharmaceutical preparations. By techniques 20 
well known in the art (U.S. Pat. No. 5,648,379; Colman, P. 
G. Protein Science 3: 1687-1696, 1994; Malby, et al., 
Structure 2: 733-746, 1994; McCoy et al., J. Molecular Biol. 
268: 570-584, 1997), substantially pure compounds or 
mimetics, may be designed. Because a substantially purified 25 
compound of the invention may be admixed with a phar-
maceutically acceptable carrier in a pharmaceutical prepa-
ration, the compound may comprise only a small percentage 
cell culture, tissue, or organism. The characteristics of the 
carrier will depend on the route of administration. Physi-
ologically and pharmaceutically acceptable carriers include 
diluents, fillers, salts, buffers, stabilizers, solubilizers, and 
other materials that are well known in the art. 
The anti-CD123 antibodies and mimetics may be labeled 
by a variety of means for use in diagnostic and/or pharma-
ceutical applications. There are many different labels and 
methods of labeling known to those of ordinary skill in the 
art. Examples of the types oflabels which can be used in the 
by weight of the preparation. The compound is nonetheless 
substantially pure in that it has been substantially separated 30 
from the substances with which it may be associated in 
living, chemical or other systems. present invention include enzymes, radioisotopes, fluores-
cent compounds, colloidal metals, chemiluminescent com-
pounds, and bioluminescent compounds. Those of ordinary 
Mimetics that Bind to CD123 
Compounds that target CD123 can be found. Phage 
display libraries can be used to determine the DNA encoding 
the polypeptide that binds to CD123. The principles of this 
approach are disclosed in U.S. Pat. No. 5,837,500, which is 
incorporated by reference herein in its entirety. Other non-
peptide molecules that may bind to CD123 include nucleic 
acids, and liposomes. Carbohydrates may also be used to 
target CD123. It is possible that the compound may not be 
a naturally occurring biological molecule. Such chemicals 
may be made by combinatorial libraries which are well 
known in the art, with the assay goal being the binding of the 
chemical compound to CD123. Liposomes may ensconce 
certain toxins or other cell-impairing substances or cell-
imaging compounds may be used to target CD123. Numer-
ous variations and combinations of compounds as targeting 
agents are contemplated by the method of the invention, so 
long as CD 123 is targeted, with the know ledge that leukemia 
detection and leukemia treatment is kept in mind. 
Mimetics of Anti-CD123 Antibodies 
It is also possible to use the anti-idiotype technology to 
isolate or screen for compounds or mimetics which mimic 
an epitope. Thus, an anti-idiotypic monoclonal antibody 
which is the image of the epitope bound by the first 
monoclonal antibody, since it effectively acts as an antigen, 
may be used to isolate mimetics from a combinatorial 
chemical, or other libraries, of chemical or other com-
pounds, such as peptide phage display libraries (Scott and 
Smith, Science 249: 386-390, 1990; Scott and Craig, Curr. 
Opin. Biotechnol. 5: 40-48, 1992; Bonnycastle et al., J. Mal. 
Biol. 258: 747-762, 1996). Hence, peptides or constrained 
peptides mimicking proteins or other compounds, including 
those with nucleic acid, lipid, carbohydrate or other moi-
eties, may be cloned (Harris et al., Proc. Natl. Acad. Sci. 
(USA) 94: 2454-2459, 1997). 
35 skill in the art will know of other suitable labels for binding 
to the CD 123 binding compound, such as monoclonal anti-
bodies, or mimetics thereof, or will be able to ascertain such, 
using routine experimentation. Furthermore, the binding of 
these labels to the CD 123 specific compounds or their 
40 mimetics can be done using standard techniques common to 
those of ordinary skill in the art. 
In the case of antibodies, another labeling technique 
which may result in greater sensitivity consists of coupling 
the antibodies or mimetics to low molecular weight haptens. 
45 These haptens can then be specifically altered by means of 
a second reaction. For example, it is common to use haptens 
such as biotin, which reacts with avidin, or dinitrophenol, 
pyridoxal, or fluorescein, which can react with specific 
anti-hapten antibodies. 
50 Diagnostic and Treatment Kits 
The materials for use in the assay of the invention are 
ideally suited for the preparation of a kit. Such a kit may 
comprise a carrier means being compartmentalized to 
receive in close confinement one or more container means 
55 such as vials, tubes, and the like, each of the container means 
comprising one of the separate elements to be used in the 
method. For example, one of the container means may 
comprise a compound that binds to CD123, such as a 
monoclonal antibody, or a mimetic thereof, which is, or can 
60 be, detectably labeled with a label that is suitable for 
diagnostic purposes or if treatment is desired, a cytotoxic or 
impairing agent. In the case of a diagnostic kit, the kit may 
also have containers containing buffer(s) and/or a container 
comprising a reporter-means, such as a biotin-binding pro-
65 tein, such as avidin or streptavidin, bound to a reporter 
molecule, such as an enzymatic or fluorescent label. In 
addition to the chemical material, of course a means of 
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instructions for using the kit is included, preferably for either 
diagnosing leukemia, or treating leukemia. The instruction 
means may be written on the vial, tube and the like, or 
written on a separate paper, or on the outside or inside of the 
container. The instructions may also be in the form of a 5 
multi-media format, such as CD, computer disk, video and 
so on. 
Preparation of Immunotoxins 
10 
containing a cleavable disulfide bond such as sulfosuccin-
imidyl-2-(p-azido salicylamido) ethyl-1,3'-dithiopropionate. 
The N-hydroxy-succinimidyl group reacts with primary 
amino groups and the phenylazide (upon photolysis) reacts 
non-selectively with any amino acid residue. 
Although the "hindered" cross-linkers will generally be 
preferred in the practice of the invention, non-hindered 
linkers can be employed and advantages in accordance 
herewith nevertheless realized. Other useful cross-linkers, While the preparation of immunotoxins is, in general, 
well known in the art (see, e.g., U.S. Pat. No. 4,340,535, and 
EP 44167, both incorporated herein by reference), the inven-
tors are aware that certain advantages may be achieved 
through the application of certain preferred technology, both 
10 
not considered to contain or generate a protected disulfide, 
include SATA, SPDP and 2-iminothiolane. The use of such 
cross-linkers is well understood in the art. 
Once conjugated, it will be important to purify the con-
jugate so as to remove contaminants such as unconjugatedA 
chain or binding agent. It is important to remove unconju-
gated A chain because of the possibility of increased toxicity. 
Moreover, it is important to remove unconjugated binding 
agent to avoid the possibility of competition for the antigen 
20 between conjugated and unconjugated species. In any event, 
a number of purification techniques are disclosed in the 
Examples below which have been found to provide conju-
gates to a sufficient degree of purity to render them clinically 
in the preparation of the immunotoxins and in their purifi-
cation for subsequent clinical administration. For example, 15 
while IgG based immunotoxins will typically exhibit better 
binding capability and slower blood clearance than their Fab' 
counterparts, Fab' fragment-based immunotoxins will gen-
erally exhibit better tissue penetrating capability as com-
pared to IgG based immunotoxins. 
Additionally, while numerous types of disulfide-bond 
containing linkers are known which can successfully be 
employed to conjugate the toxin moiety with the binding 
agent, certain linkers will generally be preferred over other 
linkers, based on differing pharmacologic characteristics and 25 
capabilities. For example, linkers that contain a disulfide 
bond that is sterically "hindered" are to be preferred, due to 
their greater stability in vivo, thus preventing release of the 
toxin moiety prior to binding at the site of action. 
useful. In general, the most preferred technique will incor-
porate the use of Blue-Sepharose with a gel filtration or gel 
permeation step. Blue-Sepharose is a colunm matrix com-
posed of Cibacron Blue 3GA and agarose, which has been 
found to be useful in the purification of immunoconjugates. 
The use of Blue-Sepharose combines the properties of ion 
exchange with A chain binding to provide good separation of 
conjugated from unconjugated binding. 
The Blue-Sepharose allows the elimination of the free 
(non conjugated) binding agent (e.g., the antibody or frag-
ment) from the conjugate preparation. To eliminate the free 
(unconjugated) toxin ( e.g., dgA) a molecular exclusion 
chromatography step is preferred using either conventional 
gel filtration procedure or high performance liquid chroma-
tography. 
After a sufficiently purified conjugate has been prepared, 
one will desire to prepare it into a pharmaceutical compo-
sition that may be administered parenterally. This is done by 
using for the last purification step a medium with a suitable 
pharmaceutical composition. 
Suitable pharmaceutical compositions in accordance with 
45 the invention will generally comprise from about 10 to about 
100 mg of the desired conjugate admixed with an acceptable 
pharmaceutical diluent or excipient, such as a sterile aque-
ous solution, to give a final concentration of about 0.25 to 
Cross-linking reagents are used to form molecular bridges 30 
that tie together functional groups of two different proteins 
(e.g., a toxin and a binding agent). To link two different 
proteins in a step-wise manner, hetero bifunctional cross-
linkers can be used which eliminate the unwanted homopo-
lymer formation. An exemplary hetero bifunctional cross- 35 
linker contains two reactive groups: one reacting with 
primary amine group (e.g., N-hydroxy succinimide) and the 
other reacting with a thiol group (e.g., pyridyl disulfide, 
maleimides, halogens, etc.). Through the primary amine 
reactive group, the cross-linker may react with the lysine 40 
residue(s) of one protein (e.g., the selected antibody or 
fragment) and through the thiol reactive group, the cross-
linker, already tied up to the first protein, reacts with the 
cysteine residue (free sulfhydryl group) of the other protein 
(e.g., dgA). 
The spacer arm between these two reactive, groups of any 
cross-linkers may have various lengths and chemical com-
positions. A longer spacer arm allows a better flexibility of 
the conjugate components while some particular compo-
nents in the bridge ( e.g., benzene group) may lend extra 50 
stability to the reactive group or an increased resistance of 
the chemical link to the action of various aspects (e.g., 
disulfide bond resistant to reducing agents). 
The most preferred cross-linking reagent is SMPT, which 
is a bifunctional cross-linker containing a disulfide bond that 55 
is "sterically hindered" by an adjacent benzene ring and 
methyl groups. It is believed that stearic hindrance of the 
disulfide bond serves a function of protecting the bond from 
attack by thiolate anions such as glutathione which can be 
present in tissues and blood, and thereby help in preventing 60 
decoupling of the conjugate prior to its delivery to the site 
of action by the binding agent. The SMPT cross-linking 
reagent, as with many other known cross-linking reagents, 
lends the ability to cross-link functional groups such as the 
SH of cysteine or primary amines ( e.g., the epsilon amino 65 
group of lysine). Another possible type of cross-linker 
includes the hetero-bifunctional photoreactive phenylazides 
about 2.5 mg/ml with respect to the conjugate. Such formu-
lations will typically include buffers such as phosphate 
buffered saline (PBS), or additional additives such as phar-
maceutical excipients, stabilizing agents such as BSA or 
HSA, or salts such as sodium chloride. For parenteral 
administration it is generally desirable to further render such 
compositions pharmaceutically acceptable by insuring their 
sterility, non-immunogenicity and non-pyrogenicity. Such 
techniques are generally well known in the art as exempli-
fied by Remington's Pharmaceutical Sciences, 16th Ed. 
Mack Publishing Company, 1980, incorporated herein by 
reference. It should be appreciated that endotoxin contami-
nation should be kept minimally at a safe level, for example, 
less than 0.5 ng/mg protein. Moreover, for human adminis-
tration, preparations should meet sterility, pyrogenicity, gen-
eral safety and purity standards as required by FDA Office 
of Biological Standards. 
A preferred parenteral formulation of the immunotoxins 
in accordance with the present invention is 0.25 to 2.5 mg 
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conjugate/ml in 0.15M NaCl aqueous solution at pH 7.5 to 
9.0. The preparations may be stored frozen at -10° C. to 
- 70° C. for at least 1 year. 
It is contemplated that most therapeutic applications of 
the present invention will involve the targeting of a toxin 5 
moiety (cytotoxic agent) to the CD123 leukemia marker. 
This is due to the much greater ability of most toxins to 
deliver a cell killing effect as compared to other potential 
agents. 
However, there may be circumstances such as when the 10 
target antigen does not internalize by a route consistent with 
efficient intoxication by immunotoxins, where one will 
desire to target chemotherapeutic agents such as cytokines, 
antimetabolites, alkylating agents, hormones, and the like. 
The advantages of these agents over their non-antibody 15 
conjugated counterparts is the added selectivity afforded by 
the antibody. One might mention by way of example agents 
such as steroids, cytosine arabinoside, methotrexate, amin-
opterin, anthracyclines, mitomycin C, vinca alkaloids, 
demecolcine, etopside, mithramycin, and the like. This list 20 
is, of course, merely exemplary in that the technology for 
attaching pharmaceutical agents to antibodies for specific 
delivery to tissues is well established. 
One preferred cytotoxic moiety for use in the present 
invention is a radioisotope, which can be coupled to or 25 
conjugated with, for example, an anti-CD123 antibody. 
Preferred radioisotopes include a-emitters such as, for 
example, 211 Astatine, 212Bismuth and 213Bismuth, as well as 
~-emitters such as, for example, 131 Iodine, 90Yttr-
ium, 177Lutetium, 153Samarium and 109Palladium. Particu- 30 
larly preferred radioisotopes are 211 Astatine and 131 Iodine. 
It is proposed that particular benefits may also be 
achieved through the application of the invention to cell 
imaging. Imaging of leukemia cells is believed to provide a 
major advantage when compared to available imaging tech- 35 
niques, in that the cells are readily accessible. 
Moreover, the technology for attaching paramagnetic, 
radioactive and even fluorogenic ions to antibodies is well 
established. Many of these methods involve the use of a 
metal chelate complex employing, for example, an organic 40 
chelating agent such a DTPA attached to the antibody (see, 
e.g., U.S. Pat. No. 4,472,509). In the context of the present 
invention the selected ion is thus targeted to the cancerous 
area by the antibody, allowing imaging to proceed by means 
12 
to which the fusion protein binds. Thus, for example, where 
the fusion protein is a growth factor joined to an antibody or 
antibody fragment (e.g. an Fv fragment ofan antibody), the 
antibody may specifically bind antigen positive cancer cells 
while the growth factor binds receptors on the surface of 
immune cells. The fusion protein may thus act to enhance 
and direct an immune response toward target cancer cells. 
In Vitro Detection and Diagnostics 
The method of using the compounds that bind to CD123 
and their mimetics are suited for in vitro use, for example, 
in immunoassays in which they can be utilized in liquid 
phase or bound to a solid phase carrier. In addition, the 
monoclonal antibodies in these immunoassays can be detect-
ably labeled in various ways. Examples of types of immu-
noassays which can utilize the monoclonal antibodies and 
their mimetics are competitive and non-competitive immu-
noassays in either a direct or indirect format. Examples of 
such immunoassays are the radioimmunoassay (RIA) and 
the sandwich (immunometric) assay. Detection of antigens 
using the monoclonal antibodies and their mimetics can be 
done utilizing immunoassays which are run in either the 
forward, reverse, or simultaneous modes, including immu-
nohistochemical assays on physiological samples. Those of 
skill in the art will know, or can readily discern, other 
immunoassay formats without undue experimentation. 
The compounds that bind CD123 and mimetics can be 
bound to many different carriers and used to detect the 
presence of CD123 bearing leukemia cells, including pro-
genitor cells. Examples of well-known carriers include 
glass, polystyrene, polypropylene, polyethylene, dextran, 
nylon, amylase, natural and modified cellulose, polyacryl-
amide, agarose and magnetite. The nature of the carrier can 
be either soluble or insoluble for purposes of the invention. 
Those skilled in the art will know of other suitable carriers 
for binding various compounds, or will be able to ascertain 
such, using routine experimentation. 
For purposes of the invention, CD123 may be detected by 
the compounds and their mimetics when present in biologi-
cal fluids and tissues. Any sample containing a detectable 
amount of CD 123 ectopeptide can be used. A sample can be 
a liquid such as urine, saliva, cerebrospinal fluid, blood, 
serum or the like; a solid or semi-solid such as tissues, feces, 
or the like; or, alternatively, a solid tissue such as those 
commonly used in histological diagnosis. 
of the attached ion. 45 In Vivo Detection of CD123 
In a preferred embodiment, in the method of the inven-
tion, the antibodies may also be fused to a protein effector 
molecule by recombinant means such as through the use of 
recombinant DNA techniques to produce a nucleic acid 
which encodes both the antibody and the effector molecule 
and expressing the DNA sequence in a host cell such as E. 
coli. The DNA encoding the chimeric protein may be cloned 
in cDNA or in genomic form by any cloning procedure 
known to those skilled in the art. See for example Sambrook 
et al, Molecular Cloning: A Laboratory Manual, Cold Spring 
Harbor Laboratory, (1989), which is herein incorporated by 
reference. 
Fusion or conjugation of antibodies to various labels 
produces a highly specific detectable marker that may be 
used to detect the presence or absence of cells or tissues 
bearing the particular molecule to which the antibody is 
detected. Alternatively, the antibodies may be chemically 
conjugated or fused to an effector molecule that is another 
specific binding moiety, e.g. a ligand such as those described 
above. In this form the composition will act as a highly 
specific bifunctional linker. This linker may act to bind and 
enhance the interaction between cells or cellular components 
In using the CD123 binding compounds and mimetics for 
the in vivo detection of CD123, the detectably labeled 
compound or its mimetic is given in a dose which is 
diagnostically effective. The term "diagnostically effective" 
50 means that the amount of detectably labeled compound, 
such as monoclonal antibody or mimetic is administered in 
sufficient quantity to enable detection of the leukemia cells 
for which the compounds or mimetics are specific. 
The concentration of detectably labeled compound or 
55 mimetic which is administered should be sufficient such that 
the binding to CD123 or CD123-bearing leukemia cells, is 
detectable compared to the background. Further, it is desir-
able that the detectably labeled compound or mimetic be 
rapidly cleared from the circulatory system in order to give 
60 the best target-to-background signal ratio. 
As a rule, the dosage of detectably labeled compound or 
mimetic for in vivo diagnosis will vary depending on such 
factors as age, sex, and extent of disease of the individual. 
The dosage of the compound can vary from about 0.01 
65 mg/kg to about 500 mg/kg, preferably about 0.1 mg/kg to 
about 200 mg/kg, most preferably about 0.1 mg/kg to about 
10 mg/kg. Such dosages may vary, for example, depending 
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on whether multiple injections are given, on the tissue being 
assayed, and other factors known to those of skill in the art. 
For in vivo diagnostic imaging, the type of detection 
instrument available is a major factor in selecting an appro-
priate radioisotope. The radioisotope chosen must have a 
type of decay which is detectable for the given type of 
instrument. Still another important factor in selecting a 
radioisotope for in vivo diagnosis is that the half-life of the 
radioisotope be long enough such that it is still detectable at 
the time of maximum uptake by the target, but short enough 
such that deleterious radiation with respect to the host is 
acceptable. Ideally, a radioisotope used for in vivo imaging 
will lack a particle emission but produce a large number of 
photons in the 140-250 keV range, which may be readily 
detected by conventional gamma cameras. 
14 
conjugated to a CD123 binding compound and delivered in 
active form to the targeted cell. Exemplary anticellular 
agents include chemotherapeutic agents, radioisotopes as 
well as cytotoxins. In the case of chemotherapeutic agents, 
5 the inventors propose that agents such as a hormone such as 
a steroid; an antimetabolite such as cytosine arabinoside, 
fluorouracil, methotrexate or aminopterin; an anthracycline; 
mitomycin C; a vinca alkaloid; demecolcine; etoposide; 
mithramycin; calicheamicin, CC-1065 and derivatives 
10 thereof, or an alkylating agent such as chlorambucil or 
melphalan, will be particularly preferred. Other embodi-
ments may include agents such as a coagulant, a cytokine, 
growth factor, bacterial endotoxin or the lipid A moiety of 
bacterial endotoxin. In any event, it is proposed that agents 
15 such as these may be successfully conjugated to antibodies 
in a manner that will allow their targeting, internalization, 
release or presentation to blood components at the site of the 
targeted leukemia cells as required using known conjugation 
For in vivo diagnosis, radioisotopes may be bound to the 
compound either directly or indirectly by using an interme-
diate functional group. Intermediate functional groups 
which often are used to bind radioisotopes which exist as 
metallic ions are the bifunctional chelating agents such as 20 
diethylenetriaminepentacetic acid (DTPA) and ethylenedi-
aminetetra-acetic acid (EDTA) and similar molecules. Typi-
technology. 
In certain preferred embodiments, cytotoxic agents for 
therapeutic application will include generally a plant-, fun-
gus- or bacteria-derived toxin, such as an A chain toxins, a 
ribosome inactivating protein, a-sarcin, aspergillin, restiric-
tocin, a ribonuclease, diphtheria toxin or pseudomonas exo-
cal examples of metallic ions which can be bound to the 
monoclonal antibodies and mimetics of the invention are 
111 In, 97Ru, 67Ga, 6sGa, n As, s9zr, 99mTc, 1231 and 201Tl. 
In the diagnosis method of the invention, the compounds 
and mimetics can also be labeled with a paramagnetic 
isotope for purposes of in vivo diagnosis, as in magnetic 
resonance imaging (MRI) or electron spin resonance (ESR). 
In general, any conventional method for visualizing diag-
nostic imaging can be utilized. Usually gamma and positron 
emitting radioisotopes are used for camera imaging and 
paramagnetic isotopes for MRI. Elements which are par-
ticularly useful in such techniques include 157Gd, 55Mn, 
l62Dy, s2cr and s6Fe. 
In the cell monitoring method of the invention, the 
compounds and mimetics can be used in vitro and in vivo to 
monitor the course of leukemia disease therapy. Thus, for 
example, by measuring the increase or decrease in the 
biological molecules associated with such a diseases or 
changes in the concentration of CD123 ectopeptide or 
CD 123 bearing leukemia cells present in the body or in 
various body fluids, it would be possible to determine 
whether a particular therapeutic regimen aimed at amelio-
rating the above leukemia disease is effective. 
Prophylaxis and Therapy of Leukemia 
The CD123 specific compounds can also be used thera-
peutically for treatment of leukemia in both humans and 
other animals. The term, "therapeutically" or "therapy" as 
used herein in conjunction with the method of the invention 
25 toxin, to mention just a few examples. The use of toxin-
antibody constructs is well known in the art of 
immunotoxins, as is their attachment to antibodies. Of these, 
a particularly preferred toxin for attachment to antibodies 
will be a deglycosylated ricin A chain. Deglycosylated ricin 
30 A chain is preferred because of its extreme potency, longer 
half-life, and because it is economically feasible to manu-
facture a clinical grade and scale. 
In other preferred embodiments, the cytotoxic agent may 
be a radioisotope. Preferred radioisotopes include a-emitters 
35 such as, for example, 211 Astatine, 212Bismuth and 213Bis-
muth, as well as ~-emitters such as, for example, 131Iodine, 
90Yttrium, 177Lutetium, 153Samarium and 109Palladium. 
As used herein, a "therapeutically effective amount" of a 
compound is a dosage large enough to produce the desired 
40 effect in which the symptoms of leukemia or the likelihood 
of onset ofleukemia is decreased. A therapeutically effective 
amount is not, however, a dosage so large as to cause 
adverse side effects, such as hyperviscosity syndromes, 
pulmonary edema, congestive heart failure, and the like. 
45 Generally, a therapeutically effective amount may vary with 
the subject's age, condition, and sex, as well as the extent of 
the disease in the subject and can be determined by one of 
skill in the art. The dosage may be adjusted by the individual 
physician or veterinarian in the event of any complication. 
50 A therapeutically effective amount may vary from about 
0.01 mg/kg to about 500 mg/kg, preferably from about 0.1 
mg/kg to about 200 mg/kg, most preferably from about 0.2 
mg/kg to about 20 mg/kg, in one or more dose administra-
is directed to using CD 123 binding compounds, such as 
anti-CD123 monoclonal antibodies and their mimetics, 
which denotes both prophylactic as well as therapeutic 
administration and both passive immunization with substan-
tially purified polypeptide products, and mimetics, as well as 55 
gene therapy by transfer of polynucleotide sequences encod-
ing the product or part thereof. Thus, the compounds and 
mimetics can be administered to high-risk subjects in order 
tions daily, for one or several days. 
In the method of the invention, the compounds and their 
mimetics can be administered by injection or by gradual 
infusion over time. The administration of the compounds 
and their mimetics may be, for example, intravenous, intra-
peritoneal, intramuscular, intracavity, subcutaneous, or to lessen the likelihood and/or severity of leukemia relapse, 
or administered to subjects already evidencing active leu-
kemia disease. 
For certain applications, it is envisioned that pharmaco-
logic agents will serve as useful agents for attachment to the 
compounds, particularly cytotoxic or otherwise anticellular 
agents having the ability to kill or suppress the growth or cell 
division of leukemia cells. In general, the invention con-
templates the use of any pharmacologic agent that can be 
60 transdermal. 
Preparations for parenteral administration include sterile 
aqueous or non-aqueous solutions, suspensions, and emul-
sions. Examples of non-aqueous solvents are propylene 
glycol, polyethylene glycol, vegetable oils such as olive oil, 
65 and injectable organic esters such as ethyl oleate. Aqueous 
carriers include water, alcoholic/aqueous solutions, emul-
sions or suspensions, including saline and buffered media. 
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The invention is described in further detail hereinbelow. 
Several recent studies have suggested the presence and 
importance of stem cells in both the genesis and perpetua-
tion of AML. Phenotypically, cells described as CD34+/ 
Parenteral vehicles include sodium chloride solution, Ring-
er's dextrose, dextrose and sodium chloride, lactated Ring-
er's or fixed oils. Intravenous vehicles include fluid and 
nutrient replenishers, electrolyte replenishers (such as those 
based on Ringer's dextrose), and the like. Preservatives and 
other additives may also be present such as, for example, 
antimicrobials, anti-oxidants, chelating agents, and inert 
gases and the like. 
Depending on the specific clinical status of the disease, 
administration can be made via any accepted systemic 
delivery system, for example, via oral route or parenteral 
route such as intravenous, intramuscular, subcutaneous or 
percutaneous route, or vaginal, ocular or nasal route, in 
solid, semi-solid or liquid dosage forms, such as for 
example, tablets, suppositories, pills, capsules, powders, 
solutions, suspensions, cream, gel, implant, patch, pessary, 
aerosols, collyrium, emulsions or the like, preferably in unit 
dosage forms suitable for easy administration of fixed dos-
ages. The pharmaceutical compositions will include a con-
ventional carrier or vehicle and a CD123 binding compound 
and, in addition, may include other medicinal agents, phar-
maceutical agents, carriers, adjuvants, and so on. 
5 CD38- or CD34+/HLA-DR- appear to play a central role in 
the development of leukemic populations (Bonnet D, et al., 
Human acute myeloid leukemia is organized as a hierarchy 
that originates from a primitive hematopoietic cell. Nat. 
Med. 1997, 3: 730-737; Blair A, et al., Most acute myeloid 
10 leukemia progenitor cells with long-term proliferative abil-
ity in vitro and in vivo have the phenotype CD34( + )/CD71 
(-)/HLA-DR-. Blood 1998, 92: 4325-35). Furthermore, 
there is evidence suggesting that such cells may be relatively 
resistant to chemotherapeutic drugs, and consequently con-
15 tribute to the phenomenon of relapse (Terpstra W, et al., 
Fluorouracil selectively spares acute myeloid leukemia cells 
with long-term growth abilities in immunodeficient mice 
and in culture. Blood 1996, 88: 1944-50). Thus, a better 
understanding of LSC biology and the characterization of 
20 unique LSC antigens are essential to the development of 
better treatments for AML. 
If desired, the pharmaceutical composition to be admin-
istered may also contain minor amounts of non-toxic aux-
iliary substances such as wetting or emulsifying agents, pH 25 
buffering agents and the like, such as for example, sodium 
acetate, sorbitan monolaurate, triethanolamine oleate, and so 
on. 
While the various AML subtypes display considerable 
diversity with respect to developmental characteristics, phe-
notype, cytokine responsiveness, etc., there appears to be a 
marked degree of functional conservation at the level of 
more primitive leukemic cells. This feature has been dem-
onstrated by the work of Bonnet et. al., in which a CD34+/ 
CD38- subpopulation was shown to be sufficient to estab-
lish leukemia in NOD/SCID mice (Bonnet D, et al., Human 
30 acute myeloid leukemia is organized as a hierarchy that 
originates from a primitive hematopoietic cell. Nat. Med. 
1997, 3: 730-737). Similar studies by others have corrobo-
rated the existence of leukemic stem cells for both AML and 
The compounds of this invention are generally adminis-
tered as a pharmaceutical composition which comprises a 
pharmaceutical vehicle in combination with a CD123 bind-
ing compound. The amount of the drug in a formulation can 
vary within the full range employed by those skilled in the 
art, e.g., from about 0.01 weight percent (wt %) to about 
99.99 wt% of the drug based on the total formulation and 35 
about 0.01 wt% to 99.99 wt% excipient. 
The preferred mode of administration, for the conditions 
mentioned above, is oral administration using a convenient 
daily dosage regimen which can be adjusted according to the 
degree of the complaint. For said oral administration, a 40 
pharmaceutically acceptable, non-toxic composition is 
formed by the incorporation of the selected CD 123 binding 
compound in any of the currently used excipients, such as, 
for example, pharmaceutical grades of mannitol, lactose, 
starch, magnesium stearate, sodium saccharine, talc, cellu- 45 
lose, glucose, gelatin, sucrose, magnesium carbonate, and 
the like. Such compositions take the form of solutions, 
suspensions, tablets, pills, capsules, powders, sustained 
release formulations and the like. Such compositions may 
contain between about 0.01 wt % and 99.99 wt % of the 50 
active compound according to this invention. 
CML and confirmed their relatively homogeneous pheno-
type and functional capacity (Blair A, Hogge et al., Most 
acute myeloid leukemia progenitor cells with long-term 
proliferative ability in vitro and in vivo have the phenotype 
CD34(+)/CD71(-)/HLA-DR-. Blood 1998, 92: 4325-35; 
Holyoake T, et al., Isolation of a highly quiescent subpopu-
lation of primitive leukemic cells in chronic myeloid leu-
kemia. Blood 1999, 94: 2056-64). However, to date, no 
study has identified an antigenic feature of myeloid LSC's 
that may allow their identification or preferential targeting 
for ablative therapy. In this report, we have identified an 
additional commonality among CD34+/CD38- AML stem 
cells, expression of CD123, which facilitates their discrimi-
nation from normal hematopoietic stem cells. While the 
CD123 antigen was readily detected at high levels onAML 
cells, the IL-3 receptor~ chain, CD131, was not detected. 
Our experiments indicate that the transcription factor 
IRF-1 (Interferon regulatory factor- I) is over-expressed (in 
6 of 6 primary AML specimens examined). Previous studies 
by Korpelainen et. al. have shown that treatment of endothe-
lial cells with IFN-y results in up-regulation of CD123 
Preferably the compositions will have the form of a sugar 
coated pill or tablet and thus they will contain, along with the 
active ingredient, a diluent such as lactose, sucrose, dical-
cium phosphate, and the like; a disintegrant such as starch or 
derivatives thereof; a lubricant such as magnesium stearate 
and the like; and a binder such as starch, polyvinylpyrroli-
done, acacia gum, gelatin, cellulose and derivatives thereof, 
and the like. 
55 (Korpelainen EI, et al., Interferon-gamma upregulates inter-
leukin-3 (IL-3) receptor expression in human endothelial 
cells and synergizes with IL-3 in stimulating major histo-
compatibility complex class II expression and cytokine 
production. Blood 1995, 86: 176-82). Similarly, our own 
It is understood that by "pharmaceutical composition", it 60 studies have shown that treatment of primary AML cells 
with IFN-y increases expression ofCD123 (data not shown). 
Thus, aberrant expression of interferon regulatory molecules 
might play a role in controlling CD123 expression in AML 
cells. 
is meant that the CD123 binding compound is formulated 
into a substance that is to be administered purposefully 
diagnosing or treating leukemia in the individual. And, by 
"pharmaceutical composition", it excludes those composi-
tions that are used to administer to individuals as test 65 
compounds for a purpose other than as a diagnostic or 
treatment agent for leukemia. 
Expression of the CD 123 antigen formally demonstrates 
that LSC's are biologically distinct from their normal stem 
cell counterparts. Because CD123 is not readily found on 
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normal hematopoietic stem cells, it provides a unique 
marker that can be used to identify malignant tissue. This 
feature may be useful for research purposes, as well as in 
minimal residual disease (MRD) studies. Further, the 
CD123 epitope represents a target to which therapeutic 5 
strategies may be directed. Previous clinical trials have used 
monoclonal antibodies against both the CD33 and CD45 
antigens as a means to deliver radioisotopes to AML cells in 
vivo (Appelbaum F R., Antibody-targeted therapy for 
myeloid leukemia. Semin Hematol 1999, 36: 2-8.). In addi- 10 
tion, several other recent studies have shown exciting results 
using monoclonal antibodies specific to antigens on malig-
nant cells such as CD20, CD52, and Her-2 (Maloney D G., 
Advances in immunotherapy of hematologic malignancies. 
Curr Opin Hematol 1998; 5: 237-43; Sikic B I., New 15 
approaches in cancer treatment. Ami Oneal 1999, 10 Suppl 
6: 149-53). Antibodies to CD123 may be useful in a similar 
paradigm and will be capable of delivering a cytotoxic hit 
that specifically targets the leukemic stem cell population. 
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using CD45-PE (Pharmingen) specific to human cells. To 
analyze cells transplanted into NOD/SCID mice, bone mar-
row was harvested at 6-8 weeks post-transplantation. Cells 
were blocked with the anti-Fe receptor antibody 2.4G2 and 
25% human serum, followed by double-labeling with 
human-specific CD34-FITC and CD45-PE antibodies. Con-
trol samples consisted of marrow cells from non-trans-
planted mice. In some cases, cells were also labeled with 
CD123-PE to ensure sustained expression of the CD123 
antigen. For each specimen 50,000-100,000 events were 
analyzed. Using this approach, human cells could reliably be 
detected to a frequency as low as 0.1 %. Any analysis falling 
below 0.1 % positive cells was considered negative. 
Example 3.-Immunoblots 
Cell samples were lysed at a concentration of 2xl07 
cells/ml in PBS containing: 1 % NP-40, 0.5% deoxycholate, 
0.1 % sodium dodecyl sulfate (SDS), 1 mM sodium vanadate 
(Na3 VO4 ), 30 µI aprotinin (Sigma), 1 mM phenylmethyl-
sulfonyl fluoride (Sigma), 1 µg/ml pepstatin, and 1 µg/ml 
leupeptin (Oncogene Research); incubated on ice for 30 
minutes, and centrifuged at 15,000xg for 10 minutes to 
remove debris. The resulting protein lysate was then ali-
We have shown that CD123 represents a unique antigenic 20 
marker for the identification of primitive leukemic cells 
from a broad range of human specimens across a broad 
range ofleukemic diseases. Our studies show that CD123 is 
generally expressed at high levels and may be indicative of 
previously uncharacterized aspects of leukemia biology. 25 quoted and stored at -80° C. For immunoblot analysis, 
protein lysates were thawed and mixed with sample buffer 
and reducing agent (Novex, San Diego, Calif., per manu-
facturer's instructions), and heated at 70° C. for 10 minutes. 
Samples were then immediately analyzed by denaturing 
The present invention will be further illustrated in the 
following, non-limiting Examples. The Examples are illus-
trative only and do not limit the claimed invention regarding 
the materials, conditions, process parameters and the like 
recited herein. 
EXAMPLES 
Example I .-Materials and Methods: Cell 
Processing 
Primary AML cells were obtained from the peripheral 
blood or bone marrow of patients. Normal bone marrow was 
obtained as waste material following pathological analysis, 
surgical marrow harvest, or from the National Disease 
Research Interchange (NDRI). Marrow cells were depleted 
of erythrocytes by suspending in 150 mM NH4Cl+10 mM 
NaHCO3 for 5 minutes, followed by two washes with 
phosphate buffered saline (PBS). Blood cells were subjected 
to Ficoll-Paque (Pharmacia) density gradient separation to 
isolate the mononuclear white blood cell compartment. 
Resulting leukocytes from marrow or blood were then used 
for immunoaffinity selection, and/or flow cytometric analy-
30 PAGE (Novex, 4-12% Bis-Tris or 7% Tris-Acetate gels) 
using the equivalent of 4xl05 cells per lane. Following 
electrophoresis, samples were electro-transferred onto 
Immobilon-P membrane (Millipore) and probed with the 
indicated antibodies. To detect CD123 (IL-3R alpha chain), 
35 antibodies S-12 (Santa Cruz Biotech) or 9F5 (Pharmingen) 
were used. For the analysis ofMek andAkt, protein-specific 
and phosphoprotein-specific rabbit polyclonal antibodies 
from New England Biolabs were used. Anti-Stat5 polyclonal 
(Transduction Labs) and anti-phospho-Stat5 (New England 
40 Biolabs) were used to analyze the phosphorylation status of 
Stat5. All primary antibodies were detected using alkaline 
phosphatase-conjugated secondary antibodies (Santa Cruz 
Biotechnology) and the ECF reagent (Pharmacia Biotech) 
per manufacturer's instructions. Blots were visualized using 
45 a Molecular Dynamics STORM 860 system and 
Imagequant™ Software. 
Example 4.-NOD/SCID Mouse Assays 
NOD/SCID mice (Jackson Laboratories, Bar Harbor, 
Me.) were exposed to 225 rads ofy-irradiation from a 137Cs 
source. Cells to be assayed were resuspended in 0.25 mis 
HBSS (Hanks balanced salt solution, Gibco) with 2% FBS 
and injected IV into the tail vein. For the analysis of some 
sis or sorting. For CD34+ cell selection, the Miltenyi immu-
noaffinity device (varioMACS) was used according to the 50 
manufacturer's instructions. In some cases, leukocytes were 
cryopreserved at a concentration of 5xl07 cells/ml in freez-
ing medium consisting of Iscoves modified Dulbecco 
medium (IMDM), 40% fetal bovine serum (FBS) and 10% 
dimethy lsulfoxide (D MSO). 55 sorted populations, lxl06 irradiated (2500 Rads) mouse 
bone marrow cells were co-injected as carrier. After 6-8 
weeks, animals were sacrificed and bone marrow was ana-
lyzed for the presence of human cells using flow cytometry 
(see above). 
Example 2.-Flow Cytometry 
Cytokine receptors were detected by labeling with the 
following monoclonal antibodies: CD 114-biotin, CD 116- 60 
FITC, CD123-PE, CD131-biotin (all from Pharmingen), 
CDl 17-PE (Coulter), and CD135-PE (Caltag). Biotinylated 
antibodies were visualized by subsequent labeling with 
streptavidin-PE (SA-PE, Becton Dickinson). PrimitiveAML 
subpopulations were identified using CD34-FITC or CD34- 65 
PE in combination with CD38-APC (Becton Dickinson). 
Primary AML cells were identified in NOD/SCID mice 
Example 5.-Results 
Analysis of cytokine receptors demonstrates strong 
expression of CD123 on primitive leukemic but not normal 
cells. Multiparameter flow cytometry was used to analyze 
the expression of cytokine receptors previously implicated 
in the growth of malignant hematopoietic cells. While 
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several receptors displayed interesting patterns of antibody 
labeling, the most striking feature observed was a remark-
ably high and well-conserved level ofCD123 (IL-3R alpha 
chain) expression amongst primary AML specimens. FIG. 1 
shows representative examples of CD 123 labeling in normal 5 
and leukemic tissue. In FIG. lA total normal marrow, as well 
as more primitive subsets, are shown with respect to CD123 
expression. Total marrow generally has about 7% positive 
cells for CD123, but only about 1 % of the population 
expresses the antigen at high levels (see inset FIG. lA). The 10 
CD34+ population of normal marrow also has readily evi-
dent CD123 expression (12% in FIG. lA, right histogram), 
as would be expected for a population known to contain 
hematopoietic progenitors. The labeling profile shown is in 
good agreement with previous studies by Sato et. al. that 15 
have also examined IL-3Ra levels on human CD34+ cells 
(Sato N, et al., Expression and factor-dependent modulation 
of the interleukin-3 receptor subunits on human hematopoi-
etic cells. Blood 1993, 82: 752-61.). However, the more 
primitive CD34+/CD38- compartment shows no significant 20 
expression ofCD123 (<1 %). In contrast, primary AML cells 
(FIG. 18) displayed high levels of CD123. In both the 
overall CD34+ population, as well as the more primitive 
CD34+/CD38- compartment, greater than 99% of the cells 
were positive for CD123. FIG. 2 shows five additional 25 
examples of CD123 labeling on CD34+/CD38-AML cells, 
further demonstrating the strong expression of this antigen 
on leukemic populations. Table 1 summarizes the experi-
ments performed to date on the AML cell type, and shows 
CD 123 levels for primitive cells of AML subtypes Ml, M2, 30 
and M4. Of the 18 primary AML specimens examined, 
CD123 was strongly expressed on the primitive leukemia 
cells in all but two instances. The two samples which had 
lower CD123 levels (samples AML-11 and AML-14, Table 
1) both displayed a uniform shift in CD123 expression, but 35 
had an overall labeling intensity that was dimmer than most 
samples assayed. In many cases (9 of 18), CD123 negative 
cells were virtually undetectable (0% or less than 1 % ). 
Conversely, expression of CD123 was not detected on 3 of 
20 
capacity of CD123+ cells, transplantation studies using the 
NOD/SCID mouse model system were performed. Three 
primary AML specimens (AML-2, 5, and 15 from Table 1) 
were assayed by flow cytometrically sorting CD34+/ 
CD123+ cells and transplanting them into irradiated NOD/ 
SCID mice. In addition, the remaining cells in the popula-
tion (CD34-/CD123+/-) were also sorted and transplanted 
in parallel. The data in FIG. 3 are a representative example 
of one specimen that showed strong engraftment of leuke-
mic cells at six weeks post-engraftment. Panel A shows total 
bone marrow cells labeled with antibodies specific to human 
CD34 and CD45. The flow cytometric profile clearly indi-
cates that a large population of human cells (CD45+) is 
present in the marrow. In addition, the population is divided 
between CD34+ and CD34- subsets, similar to the propor-
tions ofCD34 labeling seen in the original leukemic speci-
men. Panel B shows the same marrow sample gated only on 
the CD45+ cells. The data indicate that all of the cells that 
have proliferated in vivo are CD123 positive. Table 2 
summarizes the data for the three specimens tested. In all 
cases, the CD123+ cells were capable of engrafting the 
NOD/SCID animals. Moreover, in all but one instance, the 
CD123- populations did not contribute to in vivo repopu-
lation. Thus, as defined by the NOD/SCID model, we 
conclude that CD123 is expressed on the LSC. 
Finally, as an independent means of confirming the leu-
kemic origin of CD123 positive cells, flow cytometry was 
used to sort CD34+/CD123+ cells from two leukemic speci-
mens. These samples were cultured for four days, synchro-
nized and then harvested for cytogenetic analysis. Exami-
nation of spreads from each specimen showed that 20 out of 
20 metaphases was positive for the leukemia-specific trans-
location. 
Example 7.-Biological Role of CD123 Expression 
in Leukemia Cells 
To further corroborate the data obtained by flow cytom-
etry, immunoblot studies were performed to analyze IL-3R 
signal transduction components. For these studies, each 
AML sample was derived from a peripheral blood specimen 
and was sorted to isolate the CD34+ population, thus insur-
ing a virtually pure leukemic sample. First, expression of 
5 normal samples of CD34+/CD38- cells and was barely 40 
detectable in two additional specimens ( <l % ). These flow 
cytometric analyses were confirmed using two different 
anti-CD123 monoclonal antibodies to insure that the results 
were not an artifact caused by the use of a particular 
antibody. 45 both the IL-3Ra and ~ chains were examined. With respect 
to CD123, the data shown in FIG. 4 (top panel) clearly 
demonstrate expression in all leukemic samples assayed. 
The CD34+ cells derived from normal marrow (lane 2, 
CD34+) also show a weak signal. This is consistent with the 
The high level of CD123 expression found on all AML 
subtypes examined implies that IL-3Ra might play a central 
role in creating or maintaining the leukemic state. To form 
the high affinity receptor for IL-3, both the a and ~ chains 
(CD123 and CD131 respectively) are necessary. Thus, 
expression ofCD131 was also examined by flow cytometry 
on the AML specimens. Interestingly, while some expres-
sion was seen in bulk AML populations, in 15 of 15 
specimens CD131 was never detected in the CD34+ com-
partment (data not shown). 
Further data demonstrating CD123 expression in primary 
ALL and primary CML cells, as well as non-Hodgkin's 
lymphoma, are discussed in Examples 8 and 10. 
Example 6.-In Vivo Engraftment Properties of 
Human CD123+ Leukemia Cells in NOD/SCID 
Mice 
Given the strong CD123 expression observed on the vast 
majority of cells that phenotypically encompass the LSC 
population, it appeared likely that CD123 would be useful as 
a marker of LSC's. Therefore, to establish the functional 
50 data in FIG. lA, which show that normal CD34+ cells often 
contain a small subset of CD123+ cells. However, CD123 
expression was not detected by flow cytometry in the more 
primitive CD34+/CD38- subset of normal cells (FIG. lA 
and Table 1 ). Due to their low frequency, it was not possible 
55 to obtain sufficient CD34+/CD38- cells of either normal or 
AML origin for direct analysis by immunoblot. Nonetheless, 
detection of a clear signal in the overall CD34+ population 
corroborates the strong signal seen by flow cytometry for 
AML cells. Another point to note is that the molecular 
60 weight of the CD123 band appears to vary slightly between 
AML samples. We have performed RT-PCR fingerprint 
analyses of the same specimens and seen no obvious aber-
rancies (data not shown). Thus, it appears that varying 
degrees of post-translational modification are the most likely 
65 explanation for this observation. Consistent with the results 
obtained by flow cytometry, expression of CD131 was not 
detected (FIG. 4, bottom panel). 
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To begin exploring a potential functional role for CD123, 
we examined the response of primary AML cells to IL-3. 
Typically, stimulation ofhematopoietic cells with IL-3 leads 
to several well-characterized intracellular signal transduc-
tion events (Hara T, et al., Function and signal transduction 5 
mediated by the interleukin 3 receptor system in hematopoi-
esis. Stem Cells 1996, 14: 605-18). Prevalent among these 
events are phosphorylation ofMek-1, Akt, and Stat-5 (Song-
yang Z, et al., Interleukin 3-dependent survival by the Akt 
protein kinase. Proc NatlAcad Sci USA 1997, 94: 11345-50; 10 
Yagisawa M, et al., Signal transduction pathways in normal 
human monocytes stimulated by cytokines and mediators: 
comparative study with normal human neutrophils or trans-
formed cells and the putative roles in functionality and cell 15 
biology. Exp Hematol 1999, 27: 1063-76; Sutor SL, et al., 
A phosphatidylinositol 3-kinase-dependent pathway that dif-
ferentially regulates c-Raf and A-Raf. J Biol Chem 1999, 
274: 7002-10; de Groot RP, et al., Regulation of prolifera-
tion, differentiation and survival by the IL-3/IL-5/GM-CSF 20 
receptor family. Cell Signal 1998, 10: 619-28). Conse-
quently, immunoblot studies were performed on these pro-
teins to assess the degree of phosphorylation, both in the 
presence or the absence ofIL-3 stimulation. The data, shown 
in FIG. 5, show no detectable phosphorylation of Akt and 25 
Stat5 in the absence of IL-3, and only a moderate level of 
phosphorylation for Mek-1. Furthermore, in response to 
IL-3 stimulation, no appreciable increase in phosphorylation 
is seen for any of the proteins assayed. These results suggest 
that CD123 present on the surface of primary AML cells 30 
does not contribute significantly to signal transduction via 
conventional IL-3 mediated pathways. 
Example 8.----CD123 Expression in Primary ALL 
and Primary CML Cells 35 
Similar experimental protocol as described in Examples 1 
through 4 were followed, and the expression ofCD123 was 
assayed in primary ALL and primary CML cells by flow 40 
cytometry. The results were consistent with the results 
obtained with expression of CD123 in primary AML in 
Example 5. FIGS. 6A, 6B, and 6C show reproducibly that 
the primary ALL cells express CD123. Moreover, FIGS. 7A, 
7B, and 7C show reproducibly that the primary CML cells 45 
also express CD 123. 
Example 9.-CD123 Targeted Complement-Kill 
Assay 
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Example 10.----CD123 Expression in Lymphoma 
Cells 
Immunohistochemical analysis of tissue sections showed 
that "diffuse large B cell lymphoma" is strongly positive for 
expression of CD123. This is the most common form of 
non-Hodgkin's lymphoma. Thus, in a B-cell derived cancer, 
expression ofCD123 is consistent with the observation that 
CD123 was also observed on ALL cells (i.e. another type of 
B cell cancer). This observation directly identifies B cell 
lymphomas as a target for therapies and diagnostics using 
CD123. 
All of the cited references are incorporated by reference 
herein in their entirety. 
Those skilled in the art will recognize, or be able to 
ascertain using no more than routine experimentation, many 
equivalents to the specific embodiments of the invention 
specifically described herein. Such equivalents are intended 
to be encompassed in the scope of the following claims. 
Specimen 
AML 
AML-1 
AML-2 
AML-3 
AML-4 
AML-5 
AML-6 
AML-7 
AML-8 
AML-9 
AML-10 
AML-11 
AML-12 
AML-13 
AML-14 
AML-15 
AML-16 
AML-17 
AML-18 
TABLE 1 
Expression of CD123 in Primitive Leukemic 
and Normal Cells. 
% CD123+ cells in 
FAB CD34+/CD38- population 
MDS/AML 100% 
Ml 100% 
Ml 95.2% 
M4 98.1% 
M2 99.7% 
M4 99.5% 
nd 100% 
M4 99.7% 
M4 99.8% 
M2 100% 
MDS/AML 70.2% 
nd 92.5% 
Ml 97.5% 
M4 51.1% 
M4 98.1% 
Ml 95.3% 
Ml 98.9% 
M4 100% 
Normal Marrow 
BM-1 na 0 
BM-2 na <1% 
SM-3 na 0 
BM-4 na 0 
BM-5 na <1% 
FAB =French.American, British classification system 
By using a complement-kill assay, "Current protocols in 
Immunology" Edited by John Coligan, Ada Kruisbeek, 
David Margulies, Ethan Shevach, and Warren Strober, John 
Wiley and Sons publishing, 1992, which is incorporated by 
reference herein in its entirety, this experiment demonstrates 
that CD123+ cells are preferentially targeted. In this experi-
ment, we compared a typical AML specimen (i.e. CD123+) 
to a normal bone marrow sample. For each specimen there 
is an untreated control, a sample treated with complement 
alone, and a sample treated with anti-CD123+ complement. 
As shown in Table 3, there is a substantial complement-
killing effect on the AML specimen, but no effect on the 
normal marrow. This is true for both the overall sample, as 
well as the more primitive CD34+ cells. Accordingly, this 
experiment demonstrates that there is a difference between 
the effect on normal and leukemic cells with respect to the 
specificity for CD123. 
50 MDS/AML = myelodysplastic syndrome progressing to AML 
na = not applicable 
TABLE 2 
55 Engraftrnent of CD123+ Populations in NOD/SCID Mice. 
Population Cells Inj./ % CD45 + 
Exp. Specimen Assayed (N) mouse cells/recip. 
AML-2 CD34+/CD123+ (3) 4.9 X )0e6 42% 
60 
18% 
67% 
CD34-/CD123+/- (3) 7.5 X )0e5 nd 
0.2% 
0.1% 
2 AML-5 CD34+/CD123+ (4) 2.5 X )0e6 15% 
6% 
65 1% 
12% 
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TABLE 2-continued 
Engraftment of CD123+ Populations in NO D/S CID Mice. 
Exp. Specimen 
Population 
Assayed (N) 
Cells Inj./ % CD45 + 
mouse cells/recip. 
CD34-/CD123+/- (3) 2.5 x 10e6 nd 
3 AML-15 CD34+/CD123+ (5) 2.1 X 10e6 
nd 
nd 
2.1% 
0.2% 
0.8% 
1.1% 
0.9% 
CD34-/CD123+/- (3) 2.4 x 10e6 nd 
N = number of mice assayed 
nd = not detectable 
TABLE 3 
nd 
nd 
CD123 Specific Complement-Kill Assay 
Viability 
Total Cells CD34+ 
Primary AML specimen 
unstained control 68.53% 73.29% 
complement only 67.76% 77.17% 
anti-CD123 + 21.31% 33.25% 
complement 
Primary normal BM 
unstained control 80.20% 78.20% 
complement only 79.42% 80.33% 
anti-CD123 + 80.46% 81.51% 
complement 
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What is claimed is: 
1. A method for reducing the number of CD123-bearing 
leukemia cells in a human diagnosed with myelodysplastic 
syndrome, said method comprising administering to the 
5 human a therapeutically effective amount of an antibody that 
binds CD123, such that said administration causes a reduc-
tion in the number of leukemia cells in the human. 
2. The method of claim 1, wherein the therapeutically 
effective amount is a dosage of about 0.01 mg/kg to about 
10 
500 mg/kg. 
3. The method of claim 1, further comprising monitoring 
the amount of leukemia cells present in the human to 
determine that the number of leukemia cells is reduced. 
4. The method of claim 1, further comprising monitoring 
the amount of CD123-bearing leukemia cells present in the 
15 human to determine that the number of CD123-bearing 
leukemia cells is reduced. 
5. The method of claim 1, wherein the therapeutically 
effective amount of the antibody is administered to the 
human daily or for one or several days. 
20 6. The method of claim 1, wherein the antibody 1s a 
monoclonal antibody, F(ab')2 , Fab, or Fv. 
7. The method of claim 6, wherein the antibody 1s a 
monoclonal antibody. 
8. The method of claim 1, further comprising administer-
25 ing to the human an additional therapeutic agent. 
9. The method of claim 8, wherein the additional thera-
peutic agent is a chemotherapeutic agent. 
10. The method of claim 9, wherein the chemotherapeutic 
agent is a steroid cytosine arabinoside, fluorouracil, metho-
30 trexate, aminopterin, an anthracycline, mitomycin C, a vinca 
alkaloid, demecolcine, etoposide, mithramycin, calicheami-
cin, CC-1065, chlorambucil, or melphalan. 
11. The method of claim 1, wherein the antibody is 
administered intravenously, intramuscularly, subcutane-
35 ously, percutaneously, orally, parenterally, vaginally, ocu-
larly, nasally, transdermally, or intraperitoneally. 
* * * * * 
